Format

Send to

Choose Destination
Curr Opin Virol. 2014 Dec;9:154-61. doi: 10.1016/j.coviro.2014.10.001. Epub 2014 Oct 27.

Immune response to HHV-6 and implications for immunotherapy.

Author information

1
Department of Pathology, University of Massachusetts, Medical School, Worcester, MA, United States.
2
Department of Medicine, University of Massachusetts, Medical School, Worcester, MA, United States.
3
Department of Pathology, University of Massachusetts, Medical School, Worcester, MA, United States; Department of Biochemistry and Molecular Pharmacology, University of Massachusetts, Medical School, Worcester, MA, United States. Electronic address: lawrence.Stern@umassmed.edu.

Abstract

Most adults remain chronically infected with HHV-6 after resolution of a primary infection in childhood, with the latent virus held in check by the immune system. Iatrogenic immunosuppression following solid organ transplantation (SOT) or hematopoetic stem cell transplantation (HSCT) can allow latent viruses to reactivate. HHV-6 reactivation has been associated with increased morbidity, graft rejection, and neurological complications post-transplantation. Recent work has identified HHV-6 antigens that are targeted by the CD4+ and CD8+ T cell response in chronically infected adults. T cell populations recognizing these targets can be expanded in vitro and are being developed for use in autologous immunotherapy to control post-transplantation HHV-6 reaction.

PMID:
25462448
PMCID:
PMC4274602
DOI:
10.1016/j.coviro.2014.10.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center